Purpose: A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequential high-dose treatments of radioimmunotherapy with [I-131]cG250 in patients with metastasized renal cell carcinoma. Here, we report the dosimetric analysis and the relationship between the development of a human antichimeric antibody response and altered pharmacokinetics.
Experimental Design: Patients (n = 29) with progressive metastatic renal cell carcinoma received a low dose (222 MBq) of [I-131] cG250 for dosimetric analysis, followed by the first radioimmunotherapy with 2,220 MBq /M-2 [I-131]cG250 (n = 27) 1 week later. If no grade 4 hematologic toxicity was observed, a second low dose of  cG250 (n = 20) was given 3 months later. Provided that no accelerated blood clearance was observed, a second radioimmunotherapy of  cG250 was administered at an activity-dose level of 1,110 MBq /m(2) (n = 3) or 1,665 MBq/m(2) (n = 16). After each administration, whole-body images were obtained and the pharmacokinetics and the development of human antichimeric antibody responses were determined. Radiation-absorbed doses were calculated for whole body, red marrow, organs, and metastases.
Results: No correlation was found between hematologic toxicity and radiation-absorbed dose to the whole body or bone marrow, nor administered activity (MBq and MBq/kg). The tumorabsorbed doses varied largely. An inverse relation between tumor size and radiation-absorbed dose was found. Most tumor lesions received <10 Gy, whereas only lesions,<5 g absorbed > 50 Gy. A relatively high number of patients developed a human antichimeric antibody response (8 of 27) with altered pharmacokinetics, hampering additional radioimmunotherapies in four of these patients.
Conclusions: Dosimetric analysis did not adequately predict the degree of bone marrow toxicity. When human antichimeric antibody developed, the rapid clearance of radioactivity from the blood and body prohibited further treatment. According to the calculated absorbed dose in metastatic lesions, future radioimmunotherapy studies with radiolabeled cG250 should aim at treatment of small-volume disease or treatment in an adjuvant setting.
|Number of pages||9|
|Journal||Clinical Cancer Research|
|Publication status||Published - 1-Oct-2005|
|Event||10th Conference on Cancer Therapy with Antibodies and Immunoconjugates - |
Duration: 20-Oct-2004 → 23-Oct-2004
- MONOCLONAL-ANTIBODY G250
- PHASE-II TRIAL
- HEMATOLOGIC TOXICITY
- TOSITUMOMAB THERAPY
- I-131 TOSITUMOMAB
- NORMAL KIDNEY
- ANTIGEN G250